Burden of infections and preventive strategies in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies - Takeaways - MDSpire

Infection Risks and Preventive Approaches in Relapsed/Refractory Multiple Myeloma Patients Undergoing Treatment with Bispecific Antibodies

  • By

  • Sorina-Nicoleta Badelita

  • Daniel-Nicolae Murariu

  • Andreea-Lacramioara Mohorea-Neata

  • Sinziana Barbu

  • Larisa Emilia Zidaru

  • Loredana Cirlan

  • Daniel Coriu

  • July 20, 2026

Share

  • 1

    Bispecific antibodies (BsAbs) are effective for relapsed/refractory multiple myeloma (RRMM) but are associated with a high burden of infections.

  • 2

    In a study of 50 RRMM patients, 78% received prior vaccinations, with those having 3-4 vaccines showing lower infection-related mortality.

  • 3

    Anti-BCMA BsAbs led to a higher incidence and severity of infections compared to anti-GPRC5D therapy, with a shorter median time to first infection.

  • 4

    Infection-related mortality was the second leading cause of death in RRMM patients, accounting for 34% of deaths after disease progression.

  • 5

    Multivariable analyses indicated that male sex and high-risk disease were associated with an increased risk of infections in RRMM patients.

Original Source(s)

Related Content